Sector
PharmaceuticalsOpen
₹8.87Prev. Close
₹8.07Turnover(Lac.)
₹2.14Day's High
₹8.87Day's Low
₹8.8752 Week's High
₹8.0752 Week's Low
₹3.76Book Value
₹9.05Face Value
₹10Mkt Cap (₹ Cr.)
99.8P/E
62.08EPS
0.13Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 13.44 | 13.44 | 12.12 | 12.12 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -12.1 | -11.92 | -12.03 | -12.05 |
Net Worth | 1.34 | 1.52 | 0.08 | 0.06 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 0.1 | 0.13 | 0.08 | 0.05 |
yoy growth (%) | -21.23 | 61.57 | 65 | -44.19 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -0.01 | 0 | 0 | 0 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 0.02 | 0.05 | 0 | -0.01 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.02 | 0.03 | -0.01 | -0.02 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -21.23 | 61.57 | 65 | -44.19 |
Op profit growth | -57.05 | -661.27 | -52.28 | -174.27 |
EBIT growth | -57.2 | -684.21 | -51.13 | -169.92 |
Net profit growth | -57.2 | -684.21 | -51.13 | -169.92 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,809.45 | 157.2 | 4,33,367.88 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,931.55 | 86.12 | 1,58,212.64 | 518 | 0.5 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,455.65 | 28.03 | 1,18,662.51 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,348.35 | 69.01 | 1,12,895.25 | 460 | 0.84 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,668.75 | 52.77 | 1,05,776.81 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Exec. & Independent Dir.
Gagan Juneja
Independent Director
Mohd. Shahbaz Alam
Additional Director
Sitaben S Patel
Additional Director
Rajeev Mehra
Managing Director
Vishal Mehra
Company Sec. & Compli. Officer
Manowar Ali
Additional Director
Pradeep Dnyaneshwar Terse
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Welcure Drugs & Pharmaceuticals Ltd
Summary
Incorporated on 4 Jun.92, Welcure Drugs And Pharmaceuticals (WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain. The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc. WDPL had come out with a Rs 4-cr public issue in Aug.94 to part-finance the Rs 7-cr project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL). The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.96 to finance its expansion programmes.Products of WDPL include bulk drugs such as ampicillin and trimethoprim, drugs intermediates and pharmaceutical formulations. It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen. It manufactures over a hundred varieties of tablets, capsules and dry syrups, sulpha drugs, vitamins, analgesics, etc. Its subsidiary, AKL, manufactures 6-APA, a key drug intermediate in the manufacture of semi-synthetic penicillin. The company has decided to set up new sections of paediatrics and veterinary drugs and to diversify into ointments and liquid syrups. The new products of the company WELSTAP , X- CLOX , ETHAMBUTOL, RIFA- Z , CETIRIZIN , NORTIN have been well accepted in the market.The Company has entered into a collaboration agreement with a russian company to act as their sole selling agent for a unique medicine Stevioside, an alternate to sugar, S
Read More
The Welcure Drugs & Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹8.87 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Welcure Drugs & Pharmaceuticals Ltd is ₹99.80 Cr. as of 10 Dec ‘24
The PE and PB ratios of Welcure Drugs & Pharmaceuticals Ltd is 62.08 and 0.89 as of 10 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Welcure Drugs & Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Welcure Drugs & Pharmaceuticals Ltd is ₹3.76 and ₹8.07 as of 10 Dec ‘24
Welcure Drugs & Pharmaceuticals Ltd's CAGR for 5 Years at 69.31%, 3 Years at -8.86%, 1 Year at 102.76%, 6 Month at 55.19%, 3 Month at 10.10% and 1 Month at 0.00%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice